![]() Affimed N.V. Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. | ![]() Array BioPharma Array BioPharma is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. | ||||
Founding Date | Founding Date 2000 | Founding Date 1998 | Founding Date 1996 | Founding Date 1948 | Founding Date 2013 |
Type | Type Public | Type Subsidiary | Type Subsidiary | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Heidelberg, DE HQ | Locations Boulder, US HQ Chicago, US Detroit, US Houston, US Miami, US New York, US Phoenix, US | Locations Saint-Quentin-Fallavier, FR HQ | Locations South San Francisco, US HQ | |
Employees | Employees 76 | Employees 110 | Employees 2453% increase | Employees 650 | Employees 11914% increase |
Financial | |||||
Revenue (est.) | Revenue (est.) €8.3m (FY, 2023) | Revenue (est.) $173.8m (FY, 2018) | Revenue (est.) £95.9m (FY, 2015) | Revenue (est.) £731.3m (FY, 2019) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $59.4m (FY, 2018) | Cost of goods £43.1m (FY, 2015) | Cost of goods £221m (FY, 2019) | Cost of goods N/A |
Gross profit | Gross profit €13m (FY, 2023) | Gross profit $114.4m (FY, 2018) | Gross profit £52.8m (FY, 2015) | Gross profit £510.3m (FY, 2019) | Gross profit N/A |
Net income | Net income (€105.9m) (FY, 2023) | Net income ($147.7m) (FY, 2018) | Net income N/A | Net income £88.3m (FY, 2019) | Net income ($176.6m) (FY, 2021) |

Array BioPharma is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
View company
Skyepharma is a drug delivery company developing oral and inhalation products.
View company
Tricida operates in the healthcare industry focusing on pharmaceutical business.
View company